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Rivastigmine is a very important drug prescribed for the treatment of Alzheimer’s disease (AD) symp-
toms. It is a dual inhibitor, in that it inhibits both acetylcholinesterase (AChE) and butyrylcholinesterase
(BuChE). For our screening program on the discovery of new rivastigmine analogue hits for human
butyrylcholinesterase (hBuChE) inhibition, we investigated the interaction of this inhibitor with BuChE
using the complimentary approach of the biophysical method, saturation transfer difference (STD)-
NMR and molecular docking. This allowed us to obtain essential information on the key binding interac-
tions between the inhibitor and the enzyme to be used for screening of hit compounds. The main conclu-
sions obtained from this integrated study was that the most dominant interactions were (a) H-bonding
between the carbamate carbonyl of the inhibitor and the NH group of the imidazole unit of H434, (b)
stacking of the aromatic unit of the inhibitor and the W82 aromatic unit in the choline binding pocket
via p-p interactions and (c) possible CH/p interactions between the benzylic methyl group and the N-
methyl groups of the inhibitor and W82 of the enzyme.
 2016 Elsevier Inc. All rights reserved.1. Introduction
At the current time despite enormous advances in the field of
medicine we are witnessing an exponential increase in the inci-
dence of dementia in the global population. Estimates point to over
35.6 million people with dementia worldwide, a number that is
expected to double every 20 years, and is expected to reach
115.4 million cases in 2050, 60–70% of these cases have been
assigned to Alzheimer’s disease (AD) [1], the most common form
of dementia with a progressive and irreversible neurodegenera-
tion. AD is related to loss of cholinergic function, which affects
memory, learning and behavior [2,3]. A large part of the strategies
for treating AD have been based on the cholinergic hypothesis,
which postulates that memory loss in Alzheimer’s patients is asso-
ciated with a deficit of cholinergic function in the brain [4]. Theloss of cholinergic neurons leads to the progressive reduction of
acetylcholine (ACh) in the brain and resulting cognitive impair-
ment in AD [5]. ACh is hydrolyzed by both AChE and BuChE. In
order to maintain AChE levels, in AD patients, acetylcholinesterase
inhibitors (AChEIs) have been one of the prime drug targets for
controlling AD at the symptomatic level [6,7]. Those currently pre-
scribed include donepezil (Aricept), rivastigmine (Exelon), galan-
tamine (Reminyl) and tacrine (Cognex) (Fig. 1) [8]. Tacrine is a
reversible and a dual inhibitor of AChE and BuChE. It was approved
in 1993 by the FDA. However, it has been withdrawn from the mar-
ket, due to the hepatotoxicity of its metabolites [9]. As tacrine
shows excellent binding for human AChE (hAChE) and human
plasma BuChE (hpBuChE) with IC50s of 190 and 47 nM, respec-
tively, there is current interest in making tacrine analogues and
conjugates [10,11]. Galantamine, a natural product, is a reversible
and selective AChE inhibitor. It inhibits the degradation of ACh
by binding in the AChE active site [8]. It demonstrated the follow-
ing binding characteristics for heAChE and hpBuChE: IC50s of 800
and 7300 nM, respectively [11]. Donepezil is a reversible and selec-
tive AChE inhibitor. It was approved by the FDA in 1996, and has
given IC50s of 22 and 4150 nM for hAChE and hBuChE respectively
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Fig. 1. Commercialized ChE inhibitors.
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known to carbamoylate a serine residue in the active site of AChE
after binding. However, this is only transient and the enzyme
reverts back to its original form upon hydrolysis of the enzyme-
carbamate bond [11]. It was shown to furnish IC50 values of 4150
and 37 nM for the same ChEs as mentioned above [11]. Some of
its key attributes are its facile blood-brain-barrier (BBB) permeabil-
ity and it low degradation by the CYP450 cytochrome system [12].
Some important work has been published on the molecular nat-
ure of the interactions between donepezil [13] (see the work of
Brus et al. below), galantamine [14] and tacrine [10,15] with AChE.
These interactions have been studied either with X-ray crystallog-
raphy or molecular modeling (docking). The molecular nature of
AChE-rivastigmine conjugates has also been studied [16]. BuChE
is an interesting target to study as its activity increases signifi-
cantly during the latter stages of AD. It has also been shown that
increased BuChE activity also plays an important role in Ab-
aggregation during the early stages of senile plaque formation
[8b]. By contrast there is less information available on the
molecular nature of the BuChE-rivastigmine interactions. Human
BuChE (hBuChE) and human AChE (hAChE) share 65% amino acid
sequence homology [17].
In the interest of developing more potent analogues of rivastig-
mine [18] for hBuChE inhibition (which is currently a key goal of
our group), and for refining our screening methods, we undertook
a detailed study of the key interactions between BuChE and
rivastigmine using both molecular modeling and saturation trans-
fer difference (STD)-NMR. STD-NMR is a useful biophysical tool to
map ligand epitopes in close contact with the protein and to deter-
mine the level of binding between the ligand and the protein [19–
22]. We have already successfully employed STD-NMR in the case
of galantamine for determining the key interactions and binding
affinities in some of our lead compounds [14c]. For this study we
prepared an active site models based on hBuChE and hAChE
which were tested with some isoquinolinone hit compounds [14c].
2. Results and discussion
2.1. Molecular docking studies of BuChE-rivastigmine
The X-ray crystal structure of hBuChE has already been solved,
as well as an X-ray crystal structure of a hBuChE-piperidine-
containing amide complex, besides this inhibitor gave an IC50 of
21.3 nM and a dissociation constant of 2.7 nM [23]. hBuChE is char-
acterized by possessing the catalytic triad which is constituted by
S198, E325 and H438, the hydrophobic residues L286 and V288,
which define the acyl pocket, these changes make the binding with
the bulkier butyrate substrate possible [23]. Residues F288 and
F290 in AChE are replaced by L286 and V288 in BuChE [23]. The
tryptophan residue W82, interacts with the choline moiety in the
catalytic active site via a p-cation interaction. The residue D70 con-
stitutes the peripheral anionic site (PAS). In order to gain new
insights on the interaction of rivastigmine with hBuChE, so that
it could be applied in the screening of new rivastigmine analogues,we conducted some molecular docking with our model which we
had developed in a previous study [14c]. For this computational
method described elsewhere [14c] (see full details in the
supplementary information section), we prepared the hBuChE
active site from the hBuChE crystal structures obtained from the
Protein data bank as input structure (see supplementary
information). As we used EqBuChE for our bioassays and STD
studies (see below), prior to conducting our molecular modeling
studies we carried a sequence alignment study, between
EqBuChE and hBuChE (Fig. S2, supplementary information). What
we saw was an overall identity of 90% for BuChE, and no
differences were detected for the amino acid sequences within
the active sites between the human and non-human sources.
The enzymatic hydrolytic cleavage of acetylcholine (ACh) by
either BuChE or AChE results in the formation of both choline
and acetate (forming an acetylated serine moiety which is subse-
quently hydrolyzed to release the acetate) (Fig. 2). An X-ray crys-
tallography study conducted by Bar-on et al. [24] revealed that
the carbamyl moiety is covalently linked to the active-site serine
(see discussion below and Figs. 2 and 3), with the leaving group
()-S-3-[1-(dimethylamino)ethyl]phenol (NAP) being retained in
the anionic site (see discussion below). Rivastigmine is a slow sub-
strate of ChE and not a simple reversible inhibitor, it is character-
ized as a pseudo-irreversible inhibitor [24]. However, the
decarbamylation process is usually slow for ChEs [24]. It should
also be noted that NAP is also an inhibitor of ChE [24].
In the study by Bar-on et al. [24] which reported the crystal
structure of an TcAChE-rivastigmine conjugate at 2.2 Å resolution,
they showed that rivastigmine was covalently linked to the active
site S200 (equivalent to S198 in hBuChE), with the leaving group,
()-S-3-[1-(dimethylamino)ethyl]phenol (NAP), retained in the
anionic site with close association to H440, F330 and W84
(Fig. 3). Since rivastigmine is a carboxyl-esterase the role of this
serine unit which is part of the catalytic triad is crucial.
It was also observed that there was a significant movement of
H440 (equivalent to H438 in hBuChE) away from E327, from
2.52 Å in the native form to 4.01 Å in the TcAChE conjugate. This
results in the disruption of the catalytic triad, which can explain
the slow kinetics of reactivation [24]. In the TcAChE-rivastigmine
conjugate, the amino group of the carbamate moiety, with its ethyl
and methyl substituents, is oriented toward F288 in the acyl
pocket (3.2 Å). There are also aromatic-aromatic interactions of
NAP with W84 and F330 (Fig. 3). In the case of our docking studies,
in order to simplify matters since we wished to develop a rapid in
silico screening method, we maintained the intact structure within
the enzyme active site and included two water molecules, since
two water molecules were observed in the X-ray crystal structure
of Bar-on et al. [24] (Fig. 4). Significant interactions were observed,
the principle interactions being: (a) two H-bonds with the carba-
mate moiety of rivastigmine formed between the NH group of
the imidazole unit of the H438 residue and the C@O group
(2.87 Å) (this trend was also observed in the study of Brus et al.
[23]) and between the OH group of S198 and the carbonyl group
(a trend again noted in the study of Brus et al. [23]) and (b) T120
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Fig. 2. Generalized scheme for cholinesterase catalyzed hydrolysis of (a) acetylcholine – including its mode of binding within the ChE active site and (b) rivastigmine.
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Fig. 3. Simple generalized depiction of the interaction of the cleaved rivastigmine
moieties, ()-S-3-[1-(dimethylamino)ethyl]phenol (NAP) (red) and carbamate
(blue) with the TcAChE active site. Adapted from Ref. [24].
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Fig. 4. The predicted binding mode of rivastigmine to the hBuChE active site.
Hydrogen bonds are shown as green dotted lines, formed between the ligand
rivastigmine (green color) with the residues in the active site (grey color). Water
molecules in the active site are represented as red spheres. Note: the electrostatic
non-covalent and the H-Bonding interactions are shown with green lines and, a
possible CH/p interaction between W82 and the methyl and ethyl groups of the
NAP moiety is shown with a broken red-line. The assignment of the binding regions
is based on Ref. [17].
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S79 and D70 with the other water molecule. There also appears to
be a close interaction, which could possibly be a CH/p interaction
[25] between W82 and the methyl groups of the NAP moiety – this
of course is in line with the X-ray crystal analysis of Bar-on et al.
[24] only in this case there is an intact inhibitor and the residue
is W82 and not W84 (this type of interaction was also observed
in the X-ray crystal structure of the hBuChE-inhibitor conjugate
of Brus et al. [23]) To validate this study we conducted the follow-
ing STD-NMR study (see below).
2.2. Saturation Transfer Difference - Nuclear Magnetic Resonance (STD
- NMR)
We performed a key STD-NMR experiment to map the ligand-
protein interaction of rivastigmine (as its tartrate salt) with equine
EqBuChE (this was chosen because of its commercial availability atlow price). To precisely map ligand epitopes in close contact with
the protein, we acquired STD build up curves by obtaining spectra
at different saturation times [19–22]. The observed STD amplifica-
tion (ASTD) is not the same for all the hydrogens in rivastigmine.
This is due to the fact that not all the proton signals in the STD-
NMR spectrum received the same amount of saturation [19,20].
Thus, the distribution of saturation transferred among the different
compound protons indicates spatial proximities between the pro-
tons of the compound molecule and the enzyme in the bound state
[26]. A stronger intensity of a ligand’s signal in the STD-NMR spec-
trum indicates closer inter-hydrogen distances between the ligand
proton and the receptor surface in the bound state [20]. To quanti-
tatively express the relative STD effects at a given saturation time,
all of the STD signals are normalized against the most intense sig-
nal, which is arbitrarily assumed to be 100% [26]. It can be con-
cluded that protons with relative STD values close to 100%
belong to parts of the ligand that are very intimately recognized
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nificant for the interaction.
Galantamine was previously studied with EeAChE (commer-
cially available and cheap) [14c]. We conducted an STD-NMR
study of the complex formed between EeAChE and rivastigmine
(Fig. 5). In the case of rivastigmine the aromatic group of theFig. 5. STD-NMR of rivastigmine with EqBuChE, performed at 400 MHz, 15 C, and 3 s satu
EqBuChE enzyme (4 lM). (b) Binding epitope of rivastigmine from STD NMR experiment.
ligand protons and the protein active site, based on the maximum ligand STD signal (H6;
EqBuChE active site. (c) STD amplification factor as a function of saturation time for a 2NAP unit showed high STD enhancement in agreement with both
X-ray crystallography and with our docking study which was
most likely due to both p-p and CH/p interactions with the
tryptophan residue in the choline binding pocket and the
hydrophobic residues in the PAS. In addition, both the benzylic
methyl group (93%) and the N-methyl groups (38% each) of theration time. (a) Reference (top) and STD (bottom) of the rivastigmine (0.8 mM) with
The numerical values designate the fraction of saturation as percentage, between the
100%). Percentage saturation (75–100%) signifies strong interatomic contacts to the
00-fold ligand excess.
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interactions with hydrophobic residues in the PAS. The N-ethyl
group of the carbamate unit showed an intensification of almost
49%, most probably due to approximation to Y120.
As a final note, the tartrate moiety of the rivastigmine also
showed some significant enhancement at the H-19 and H-21
(74% and 68%, respectively, Fig. 5). However, it is unknown
whether this can interfere with the rivastigmine-enzyme binding.
3. Conclusions
When screening for hit and lead compounds, nimble yet reliable
biophysical and/or non-biological methods, can be very useful, sav-
ing both time and expense. In our efforts at screening for new
rivastigmine analogue hits showing good affinity for hBuChE we
required rapid and reliable biophysical protocols to determine
their binding affinities. We carried out a thorough molecular mod-
eling docking study of rivastigmine in the active site of a hBuChE
construct based on X-ray crystal structures and validated this by
carrying out an STD-NMR study of the same inhibitor with
EqBuChE. The main conclusions that we obtained from these stud-
ies were that for the design of appropriate rivastigmine analogues
the essential interactions appear to be (a) p-p and CH/p interac-
tions between the aromatic unit of the inhibitor with the W82 in
the choline binding pocket and (b) the benzylic methyl group
and the N-methyl groups of the NAP unit most probably with
W82. Thus it seems important that potent rivastigmine analogues
contain such pharmacophores in these positions relative to the
enzyme active site residues. Currently we are preparing novel
rivastigmine analogues based on this information, these results
will be reported in due course.
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